Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells $93,100.00 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $9.31, for a total value of $93,100.00. Following the completion of the sale, the director now directly owns 180,339 shares of the company’s stock, valued at $1,678,956.09. The sale was disclosed in a filing with the SEC, which is available at this link.

Arcutis Biotherapeutics Stock Performance

Shares of NASDAQ ARQT opened at $9.60 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 9.61 and a current ratio of 9.89. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -3.28 and a beta of 1.18. The business’s 50-day simple moving average is $8.62 and its 200-day simple moving average is $7.88. Arcutis Biotherapeutics, Inc. has a 52 week low of $1.76 and a 52 week high of $13.17.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.28. The business had revenue of $49.57 million for the quarter. Arcutis Biotherapeutics had a negative return on equity of 197.28% and a negative net margin of 204.35%. During the same period in the prior year, the company posted ($1.31) EPS. As a group, equities research analysts expect that Arcutis Biotherapeutics, Inc. will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Needham & Company LLC upped their target price on Arcutis Biotherapeutics from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Mizuho upped their target price on Arcutis Biotherapeutics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.38.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Cape Investment Advisory Inc. acquired a new stake in Arcutis Biotherapeutics in the 4th quarter valued at approximately $26,000. Cantor Fitzgerald L. P. acquired a new stake in Arcutis Biotherapeutics in the 4th quarter valued at approximately $33,000. Victory Capital Management Inc. acquired a new stake in Arcutis Biotherapeutics in the 4th quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. grew its holdings in Arcutis Biotherapeutics by 586.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,920 shares of the company’s stock valued at $35,000 after buying an additional 9,330 shares during the last quarter. Finally, Amalgamated Bank grew its holdings in Arcutis Biotherapeutics by 48.9% in the 4th quarter. Amalgamated Bank now owns 11,078 shares of the company’s stock valued at $36,000 after buying an additional 3,639 shares during the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.